Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948142 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
A Phase 2 study, sponsored by Arrevus.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
NCT00948142: Completed Phase 2 study, sponsored by Arrevus.
NCT00948142 is a Phase 2 study that has completed, run by Arrevus. The registered enrollment target is 198 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00948142, a Phase 2 study, has completed, sponsored by Arrevus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of CEM-102 compared to Linezolid in the treatment of acute bacterial skin structure infections (ABSSIs).
Interventions
- DRUG Linezolid
- DRUG CEM-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00948142
The ClinicalTrials.gov registry entry for NCT00948142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrevus, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Linezolid is the first listed.
NCT00948142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00948142 about?
NCT00948142 is a clinical study titled "Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections". The purpose of this study is to determine the safety and efficacy of CEM-102 compared to Linezolid in the treatment of acute bacterial skin structure infections (ABSSIs).
What is the current status of trial NCT00948142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2009-08. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00948142?
The interventions under investigation include: Linezolid (DRUG), CEM-102 (DRUG).
Who is sponsoring clinical trial NCT00948142?
This trial is sponsored by Arrevus, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.